Micropos Medical (MPOS) Q2 2025 earnings summary

Executive summary

• Net sales for Jan–Jun 2025 reached 5,979 Tkr, up from 2,012 Tkr year-over-year; Q2 sales were 3,349 Tkr versus 1,200 Tkr last year.

• Result after financial items improved to -9,803 Tkr from -11,636 Tkr year-over-year.

• 350 patients have been treated with Raypilot System, with growing clinical acceptance and market interest.

• Major presence and successful seminar at ESTRO 2025, driving new contacts and awareness for ASBRT.

• New installations in Ireland and Italy, and first treatments in Switzerland and Spain.

Financial highlights

• Net sales for Jan–Jun 2025: 5,979 Tkr (2,012 Tkr); Q2: 3,349 Tkr (1,200 Tkr).

• Result after financial items: -9,803 Tkr (-11,636 Tkr) for Jan–Jun; Q2: -4,277 Tkr (-6,382 Tkr).

• Equity at period end: 25,591 Tkr (20,363 Tkr); cash and equivalents: 21,073 Tkr (18,501 Tkr).

• Soliditet (equity ratio): 83% (74%).

• Result per share: -0.06 kr (-0.08 kr) for Jan–Jun; -0.03 kr (-0.04 kr) for Q2.

Outlook and guidance

• Continued focus on market expansion, especially in Europe, and on establishing ASBRT as a new standard.

• Ongoing MDR certification process, with completion targeted for autumn 2025.

• Precision study delayed but expected to scale up after summer; new study on patient quality of life planned.